As a supplementary on that, the initial business plan for the CDR projected that we would be reviewing 25 new drugs per year. In the first two years of the CDR, that's what happened. In the past year, we received 40 submissions.
Why? I'm not quite sure. It could have been that Health Canada has now caught up on their backlog and those drugs have flowed downstream to us and CDR. So additional resources were applied in the past year to accommodate that increased workload.